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ABSTRACT Infection with the dimorphic fungus Histoplasma capsulatum results from the inhalation of contaminated soil. Dis-
ease outcome is variable and depends on the immune status of the host, number of organisms inhaled, and the H. capsulatum
strain. H. capsulatum is divided into seven distinct clades based on phylogenetic analyses, and strains from two separate clades
have been identified in North America (denoted as NAm strains). We characterized an H. capsulatum isolate (WU24) from the
NAm 1 lineage in relation to two other well-characterized Histoplasma isolates, the Panamanian strain G186A and the NAm 2
strain G217B. We determined that WU24 is a chemotype II strain and requires cell wall -(1,3)-glucan for successful in vitro
infection of macrophages. In a mouse model of histoplasmosis, WU24 exhibited a disease profile that was very similar to that of
strain G186A at a high sublethal dose; however, at this dose G217B had markedly different kinetics. Surprisingly, infection with a
lower dose mitigated many of the differences during the course of infection. The observed differences in fungal burden, disease
kinetics, symptomology, and cytokine responses all indicate that there is a sophisticated relationship between host and fungus
that drives the development and progression of histoplasmosis.
IMPORTANCE Histoplasmosis has a wide range of clinical manifestations, presenting as mild respiratory distress, acute respira-
tory infection, or a life-threatening disseminated disease most often seen in immunocompromised patients. Additionally, the
outcome appears to be dependent on the amount and strain of fungus inhaled. In this study, we characterized a recent clinical
H. capsulatum isolate that was collected from an HIV individual in North America. In contrast to other isolates from the same
lineage, this strain, WU24, infected both macrophages and wild-type mice. We determined that in contrast to many other North
American strains, WU24 infection of macrophages is dependent on the presence of cell wall -(1,3)-glucan. Surprisingly, com-
parison of WU24 with two previously characterized isolates revealed that many conclusions regarding relative strain virulence
and certain hallmarks of histoplasmosis are dependent on the inoculum size.
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Histoplasma capsulatum is endemic to soils throughout theworld and is one of the most common fungal respiratory
pathogens. In areas where the fungus is prevalent, more than 80%
of the human population is positive for a Histoplasma antigen skin
test, indicating previous exposure or infection (1, 2). Histoplas-
mosis presents with diverse manifestations, including mild sub-
clinical disease, acute respiratory distress, and systemic dissemi-
nation. Disease outcome varies, depending on the immune status
of the host and the quantity of organisms inhaled (3–5). H. cap-
sulatum is one of the classic dimorphic fungal pathogens, a group
that consists of six primary human pathogens that also includes
Blastomyces dermatitidis, Coccidioides immitis, Paracoccidioides
brasiliensis, Sporothrix schenckii, and Penicillium marneffei. This
group of pathogens is defined by their temperature-dependent
transition from a saprophytic mold to a parasitic yeast form (a
spherule in the case of C. immitis) upon transition into a mam-
malian host (6, 7). For H. capsulatum, the ability to convert from
the hyphal to unicellular yeast form is required for virulence (3–5,
8–11).
Until recently, H. capsulatum was divided into three distinct
subspecies that were determined by geographical distribution and
clinical symptoms. This classification system subdivided H. cap-
sulatum into New World human pathogens (H. capsulatum var.
capsulatum), African human pathogens (H. capsulatum var.
duboisii), and Old World horse pathogens (H. capsulatum var.
farciminosum). A more recent comprehensive phylogeographic
study of isolates from around the world reclassified H. capsulatum
into at least 7 distinct clades that correlate with their region of
geographic isolation (12, 13). The composition of the fungal cell
wall is also used to further classify H. capsulatum strains into two
chemotypes (14, 15). Isolates lacking the polysaccharide -(1,3)-
glucan in their cell wall are designated chemotype I. Chemotype I
RESEARCH ARTICLE
July/August 2014 Volume 5 Issue 4 e01376-14 ® mbio.asm.org 1
isolates all belong to the North American 2 (NAm 2) group. All
other H. capsulatum clades are classified as chemotype II and have
-(1,3)-glucan in their cell walls, which is required for virulence
and immune evasion (16). Spontaneous -(1,3)-glucan mutants
arise during repeated passaging, which enriches for nonclumping
yeast. Loss of -(1,3)-glucan results in virulence attenuation for
chemotype II strains (17–20). Chemotype I strains are virulent
despite the absence of -(1,3)-glucan (16, 19, 21, 22).
Most reports on H. capsulatum pathogenesis and virulence fo-
cus on two clinical isolates from phylogenetically distinct groups:
G186A, a chemotype II strain of Panamanian origin, and G217B, a
chemotype I strain of the NAm 2 clade (Table 1). In mouse models
of infection, disease progression in the lungs is similar for both
strains. Fungal burden in the lungs peaks at 8 days postinoculation
(dpi); however, overall burden is higher in animals infected with
G217B. When inoculated at high doses, G217B causes greater
mortality than G186A (23–25). Although the virulence and patho-
genesis of these two strains have been compared, most studies
have focused on the acute phase of the disease and have not eval-
uated disease resolution. Additionally, comparisons have involved
a relatively high inoculating dose (1  105 to 1  107 cells admin-
istered intranasally), which is likely much higher than would be
found in contaminated soil. Furthermore, virulence of each strain
has been determined by counting organ fungal burden or deter-
mining the 50% lethal dose and not by comparing other features
of disease, including relative lung damage, inflammation, and res-
olution of infection. A minimal number of Histoplasma particles
(either yeast or conidia) are required to establish infection, and
the capacity to initiate infection is dramatically reduced when
fewer particles are used (4, 26). The effect of inoculum size on
disease progression has not been examined previously in a direct
strain comparison.
In North America, H. capsulatum strains from two different
clades, NAm 1 and NAm 2, are routinely isolated from patients.
Members of the NAm 1 clade are thought to be associated with
HIV-positive or otherwise-immunocompromised patients. NAm
2 infection appears to be more widespread and does not correlate
with host immune status (3, 27, 28). The NAm 2 isolate G217B has
been extensively studied; however, less is known about NAm 1
strains. The canonical NAm 1 isolate, Downs, was isolated from an
80-year-old woman with disseminated histoplasmosis and is at-
tenuated for virulence in a murine histoplasmosis model (27, 28).
This strain has been heavily passaged, which is likely responsible
for the loss of virulence. WU24 was collected from an HIV pa-
tient in St. Louis, MO, which is located within a region where
histoplasmosis is endemic. Like the well-characterized Panama
isolate, G186A, and the NAm 2 isolate, G217B, the genome of
WU24 has been fully sequenced (29), and a sequence comparison
between WU24, G186A, and G217B reveals substantial differ-
ences. G186A and WU24 have much smaller genomes (30.4 Mb
and 30.99 Mb, respectively) than G217B (41-Mb genome), and
the G217B genome contains many repetitive elements, including
retrotransposons, mobile DNA insertions, and cryptons,
throughout the chromosomes (30, 31).
We characterized the NAm 1 isolate, WU24, in comparison to
G186A (Panama clade) and G217B (NAm 2 clade) in macrophage
virulence assays and a murine model of histoplasmosis. We also
evaluated the effect of inoculum size on disease progression and
fitness for each strain, as well as their ability to cause inflammation
in the lungs. Our observations challenge the current presump-
tions about the virulence of the NAm 1 clade and illustrate the
complexity of assessing relative strain virulence in experimental
models of histoplasmosis.
RESULTS
Histoplasma capsulatum clinical isolate WU24 is a chemotype
II strain. WU24 was originally isolated in 2003 from an HIV
patient in St. Louis, MO, but it has not been fully characterized in
the laboratory. In its yeast form at 37°C, this strain grows in large
clumps in liquid culture and exhibits a rough colony morphology
on solid medium (Fig. 1C), similar to the previously characterized
chemotype II isolate G186A (Fig. 1A). We generated a spontane-
ous -(1,3)-glucan-negative mutant of WU24 by enriching for
nonclumping yeasts, as previously described for G186A (19). This
strain, WU24S, exhibited a smooth colony morphology on solid
medium (Fig. 1D) that was comparable to that of the chemotype I
strain G217B (Fig. 1E) and an -(1,3)-glucan mutant [ags1()] of
G186A (Fig. 1B). We used a monoclonal antibody against -(1,3)-
glucan to evaluate the presence of this polysaccharide in the cell
wall of G217B, G186A, ags1(), WU24, and WU24S by immuno-
fluorescence microscopy (Fig. 1K to O). The cell walls of G186A
and WU24 stained brightly with the anti--(1,3)-glucan antibody
(Fig. 1K and M), while ags1(), WU24S, and G217B had no de-
tectable -(1,3)-glucan (Fig. 1L, M, and O). The presence of
-(1,3)-glucan leads to classification of WU24 as a chemotype II
strain (14, 15).
Spontaneous loss of -(1,3)-glucan impairs the ability of
WU24 to kill macrophages in vitro. We evaluated the require-
ment of -(1,3)-glucan for WU24 to kill macrophages in vitro.
Bone marrow-derived macrophages (BMDMs) were infected at a
multiplicity of infection (MOI) of 0.3 (1 yeast:3 macrophages)
with G186A, ags1(), WU24, or WU24S, and macrophage sur-
vival was determined after 7 days (Fig. 2). Macrophage survival
was calculated as the amount of macrophage DNA remaining after
incubation of macrophages with H. capsulatum, normalized to the
amount of macrophage DNA from an uninfected macrophage
monolayer. At 7 dpi, both WU24 and G816A had destroyed the
majority of the monolayer, indicating that WU24 is also able to
infect and eliminate macrophages in vitro. As previously reported,
ags1() did not clear the macrophage monolayer, and WU24S was
also completely impaired for macrophage killing. The require-
TABLE 1 H. capsulatum strains used in this study
Strain Chemotype Genotype or description Source Isolate source/location
G186A II H81 lineagea ATCC 26029 Human/Panama
WU24 II NAm 1 cladeb This study Human, HIV/Missouri
G217B I NAm 2 cladea ATCC 26032 Human/Los Angeles
a Kasuga et al. (12, 13).
b Histoplasma capsulatum database of the Broad Institute (29).
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ment of -(1,3)-glucan for in vitro macrophage killing of WU24
further supports the classification of this strain as chemotype II.
Kinetics of in vitro macrophage killing by H. capsulatum
strains. Previous studies demonstrated that G217B effectively in-
fects and destroys cultured macrophages (18, 32, 33). We com-
pared the kinetics of in vitro macrophage killing among the three
H. capsulatum strains (Fig. 3). P388D1 macrophages were infected
with G186A, G217B, or WU24 at an MOI of 0.3, and macrophage
survival was measured at 3, 6, and 9 dpi. Macrophage DNA at each
time point was normalized to the amount in populations of mac-
rophages, as described above. Strain G186A began to clear the
macrophage monolayer as early as 3 dpi; however, there was no
discernible killing in WU24- or G217B-infected macrophages at
this time. At 6 dpi, WU24 and G186A exhibited similar levels of
macrophage clearance, and both of these strains had completely
destroyed the monolayer by 9 dpi. In G217B-infected macro-
phages, no detectable killing was observed until 9 dpi. This delay
in lysis of host macrophages was not due to any apparent defect in
intracellular replication of G217B (see Fig. S1 in the supplemental
material). A similar pattern of kinetics was observed in G186A-
infected, WU24-infected, and G217B-infected BMDMs (data not
shown).
In vivo virulence of H. capsulatum at a high sublethal dose.
Clinical histoplasmosis is often symptomatic but rarely lethal in
immunocompetent human hosts. We therefore chose a sublethal
dose to characterize the course of disease during experimental
infection of mice, which are natural hosts of H. capsulatum. To
compare the fungal strain fitness in vivo, C57BL/6 mice were in-
oculated intranasally with 2.5  105 G186A, WU24, or G217B
yeast cells, and fungal burdens in the lungs were evaluated
throughout the acute phase and resolution phase of disease
(Fig. 4A). At days 0 and 4, there was no difference in pulmonary
fungal burden between the three strains. Fungal burden peaked in
the lungs at 8 dpi for all three strains; however, G217B-infected
mice had a higher fungal burden than either WU24-infected or
FIG 1 Colony morphology and -(1,3)-glucan immunostaining. (A to E) Colony morphology of G186A (A) and WU24 (C), both chemotype II strains, which
showed rough colony morphology, chemotype I strain G217B (E), which had smooth colony morphology, and also strains G186A ags1() (B) and spontaneous
mutant WU24S (D). (F to J) Phase-contrast microscopy images of yeast broth cultures. (K to O) -(1,3)-glucan immunostaining. The smooth colony morphol-
ogy correlates with the absence of -(1,3)-glucan in the yeast cell wall, as shown by immunofluorescence.
FIG 2 Spontaneous loss of -(1,3)-glucan impairs the virulence of WU24
yeast cells in macrophages. Macrophage survival was measured as the reduc-
tion in macrophage DNA remaining after incubation of macrophages with
Histoplasma yeast cells. Macrophage DNA remaining at 7 days postinoculation
was normalized to that in uninfected populations of macrophages. Data rep-
resent results from three independent assays. Error bars represent the standard
errors of the means.
FIG 3 The virulence kinetics of the G217B strain is delayed in vitro. Macro-
phage survival was measured as the reduction in macrophage DNA remaining
after incubation of macrophages with Histoplasma yeast cells. Macrophage
DNA remaining at 3, 6, and 9 days postinoculation was normalized to that in
uninfected populations of macrophages. Data represent results of two inde-
pendent assays. Error bars represent the standard errors of the means.
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G186A-infected mice. The kinetics of fungal infection with WU24
and G186A were comparable, but the resolution phase of G217B
infection lasted longer.
Histological examination of infected lungs revealed the pres-
ence of monocytic cell infiltrate in the lungs at 8 dpi for all three
strains (Fig. 5A, F, and K; see also Fig. S2 in the supplemental
material). At 12 dpi, there were no noticeable differences in the
pattern or the extent of pulmonary immune cell infiltrate (Fig. 5B,
G, and L), even though G217B-infected animals had markedly
increased fungal burdens. By 16 dpi, the inflammatory damage in
the lungs of WU24-infected mice had started to resolve (Fig. 5M),
and it was barely detectable at 20 dpi (Fig. 5N). Despite the differ-
ences in fungal burdens, mice infected with G217B or G186A had
similar lung pathologies through 16 dpi (Fig. 5C and H). By day
32, only lungs from G217B-infected mice had any residual inflam-
mation (Fig. 5E, J, and O).
Other parameters of infection correlated with the kinetics of
histopathology caused by these three strains. Mice infected with
G217B had noticeable weight loss between days 8 and 16, losing an
average of ~20% of their body weight (Fig. 6). G217B-infected
mice began to regain weight at 16 dpi. Both G186A-infected and
WU24-infected mice lost weight until 14 dpi, but the change in
weight was substantially less than that observed for G217B-
infected mice. We also compared the induction of several proin-
flammatory cytokines in the lungs of H. capsulatum-infected ani-
mals. The cytokines evaluated included tumor necrosis factor
alpha (TNF-), gamma interferon (IFN-), interleukin-1 (IL-
1), and IL-12 (Fig. 7), which have been implicated in controlling
Histoplasma infection (34–39). Cytokines were measured from
lungs collected at 8 dpi, which correlates to the peak of infection
and the infiltration of monocytes into the lung (Fig. 5). Addition-
ally, lung cytokine levels were determined at 20 and 32 dpi, which
FIG 4 Histoplasma fitness in vivo, evaluated using a high sublethal dose. The chart depicts the number of CFU recovered from the lungs 0 (4 h), 4, 8, 12, 16, 20,
and 32 days postinoculation, using 2.5  105 yeast cells as the inoculum (high sublethal dose). Data represent results from two independent assays. Bars represent
the medians. *, Mann-Whitney test, P  0.05; blue asterisks, significant differences between G217B and G186A; green asterisks, significant differences between
G217B and WU24. The limit of detection is denoted by a dotted line.
FIG 5 H&E-stained sections of lungs from mice inoculated intranasally with 2.5  105 yeast cells. Sections of lungs from mice infected with G186A, G217B, and
WU24 were analyzed 8, 12, 16, 20, and 32 days postinoculation. Representative sections of the Histoplasma-infected lungs are shown. The G217B strain caused
more noticeable lung damage than did either the G186A or WU24 strains in mice infected using a high sublethal dose.
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correspond to the resolution phase of the disease. At 8 dpi, lungs
from G217B-infected mice had significantly higher levels of IFN-
(Fig. 7A) and TNF- (Fig. 7B) than G186A-infected or WU24-
infected mice. The levels of IL-1 were significantly higher in
lungs of animals infected with G217B than in those infected with
G186A, but these levels were not statistically different from the
WU24 group (Fig. 7C). G217B induced higher levels of IL-12 in
lungs than did WU24 (Fig. 7D), but not compared to G186A.
Substantial differences in proinflammatory cytokine induction
were only observed at 8 dpi. This time point correlates with peak
fungal burden, which was much higher in animals infected with
G217B. There was no difference in cytokine levels between strains
during the resolution phase (20 and 32 dpi).
Collectively, these data indicate that G217B has a fitness advan-
tage at a high sublethal dose, causing more severe disease in mice
than do G186A or WU24. Additionally, it is clear that WU24, a
member of the NAm1 clade thought to only cause illness in im-
munocompromised hosts, is able to establish infection in an im-
munocompetent host. The kinetics and pathology of WU24 infec-
tion are very similar to those of another chemotype II strain,
G186A.
In vivo virulence of Histoplasma strains at a low sublethal
dose. Given that clinical H. capsulatum infection results from the
inhalation of contaminated soil, natural infection in humans
probably occurs at doses much lower than what are typically eval-
uated experimentally. In an attempt to test a more clinically rele-
vant dose of H. capsulatum, we infected male C57BL/6 mice with
2.5  103 yeast cells of G186A, WU24, or G217B; this corre-
sponded to an intranasal inoculum that was at least 10 times lower
than the doses employed in any previously published study of
experimental histoplasmosis. At this low sublethal dose, early in-
fection kinetics reflected the high sublethal dose, with lung fungal
burden peaking at 8 dpi. Surprisingly, the amplification of fungal
burden was nearly 10 times greater at this dose than with the high
sublethal dose (Fig. 8A). Infection with the lower dose resulted in
similar pulmonary fungal burdens in G217B-infected, G186A-
infected, and WU24-infected animals at each time point. These
kinetics, particularly during the resolution phase of the disease,
contrasted sharply with those for the infection with a high sub-
FIG 6 Mice infected with the G217B strain showed a dramatic loss of weight.
The percent weight loss/gain of mice infected with G186A, G217B, and WU24
was monitored during the course of infection. ***, P  0.001, one-way analysis
of variance with Bonferroni posttest; blue asterisks, significant differences be-
tween G217B and G186A; green asterisks, significant differences between
G217B and WU24.
FIG 7 Levels of cytokines measured by ELISA in lungs infected with 2.5  105 yeasts at 8, 20, and 32 days postinoculation. (A) IFN-; (B) TNF-; (C) IL-1;
(D) IL-12. A two-way repeated-measures analysis of variance was performed. *, P  0.05; **, P  0.01; ***, P  0.001.
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lethal dose. G217B was cleared more rapidly at a lower dose, but
G186A and WU24 (both chemotype II strains) were cleared more
slowly. With the high doses of G186A and WU24, fungal burdens
in the lungs dropped to levels that were below the initial inoculum
at 20 dpi (Fig. 4); however, at the low dose, fungal burdens at 20
dpi were still greater than the initial inoculum (Fig. 8). By day 32,
all three strains were undetectable in the lungs.
Histological examination of the lungs from these mice revealed
small foci made up primarily of monocytic cell infiltrate at 8 dpi
(Fig. 9A, F, and K) and 12 dpi (Fig. 9B, G, and L). This monocytic
cell infiltration was more evident at 16 dpi for all three strains
(Fig. 9C, H and M). At 20 dpi, resolution of inflammation began
in the lungs of mice infected with G217B (Fig. 9I) and WU24
(Fig. 9N), but not in G186A-infected mice (Fig. 9D). By day 32
there was no evidence of any residual inflammation in mice in-
fected with any of the three strains (Fig. 9E, J, and O). These results
demonstrated that H. capsulatum can establish a pulmonary in-
fection with a relatively small inoculum size. Both the fitness ad-
vantage and delayed resolution of inflammation observed in mice
infected with a high sublethal dose of G217B were ameliorated
when a lower dose was used. Surprisingly, at a lower dose, resolu-
tion of inflammation was slowest in the lungs of G186A-infected
mice, despite no difference in pulmonary fungal burdens. None of
the mice infected at this dose had any evident weight loss (data not
shown).
Because IFN- and TNF- levels were different in the lungs of
mice infected with the three different strains at a high sublethal
dose, we evaluated the levels of these cytokines in lungs during
infection with a lower dose. Comparison of the strain-specific
induction of IFN- and TNF- during the complete course of
infection (Fig. 10) revealed that there was no difference in cyto-
kine levels at any time during low-dose infection (Fig. 10A and B).
These data suggest that the induction of IFN- and TNF- is
linked to the number of organisms in the lungs, which was equal
for G217B-infected, WU24-infected, and G186A-infected animals
at this dose.
FIG 8 Histoplasma fitness in vivo, evaluated using a low sublethal dose. The chart depicts the number of CFU recovered from the lungs after 0 (4 h), 4, 8, 12, 16,
20, and 32 days postinoculation, using 2.5  103 yeast cells as the inoculum (low sublethal dose). Bars represent medians. *, P  0.05, Mann-Whitney test. The
limit of detection is denoted by a dotted line.
FIG 9 H&E staining of lungs of animals infected with 2.5  103 yeast cells. Lung sections from animals infected with G186A (A to E), G217B (F to J), and WU24
(K to O) were analyzed 8, 12, 16, 20, and 32 days postinoculation. Representative lung sections from the Histoplasma-infected mice are shown. The G186A strain
caused more noticeable lung damage than did either the G217B or WU24 strain in mice infected with a low sublethal dose.
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DISCUSSION
In this study, we compared virulence in three sequenced H. cap-
sulatum isolates by using in vitro and in vivo models of infection.
Based on sequence comparisons, G186A and G217B are predicted
to have diverged fairly recently. WU24, a NAm 1 isolate, is the
most disparate of the three isolates, but it appears to have many of
the same virulence factors as G186A. The NAm 1 clade has histor-
ically been associated with immunocompromised individuals,
and isolates are typically avirulent in animal models of infection
(18, 27, 28, 40). We evaluated the ability of the WU24 strain to
cause disease in an immunocompetent host compared to G217B
and G186A, which have been well characterized in several in vivo
and in vitro histoplasmosis models. Using two different inoculum
sizes in a mouse model of sublethal histoplasmosis, we observed
isolate-specific and dose-specific differences in disease between
the three strains, complicating any conclusions regarding which
strain may be more or less virulent.
-(1,3)-glucan has been linked to strain-specific virulence in
H. capsulatum and several other fungal pathogens, including the
dimorphic fungi Paracoccidioides brasiliensis (41) and Blastomyces
dermatitidis (42); however, the specific function of -glucan for
each pathogen may be different. For example, -(1,3)-glucan in
Cryptococcus neoformans has been shown to anchor the capsule to
the cell wall (43), while in H. capsulatum, -(1,3)-glucan appears
to mask yeast cells from recognition by the innate immune
-glucan receptor dectin-1 (16). Interestingly, -(1,3)-glucan
mutants of H. capsulatum chemotype II are not completely killed
in vitro by macrophages, yet they are unable to proliferate or lyse
macrophages and are markedly attenuated in mouse models of
histoplasmosis (18, 19, 21). Despite the requirement of this poly-
saccharide for virulence in the majority of H. capsulatum strains,
isolates from the NAm 2 clade have evolved or maintained viru-
lence in the absence of -(1,3)-glucan. H. capsulatum exists pri-
marily in the soil, where there is no known advantage to produc-
ing -(1,3)-glucan, yet the majority of isolates produce this cell
wall component upon transition into a host. This is not surprising,
as collection and identification of H. capsulatum isolates have de-
pended on the organisms’s ability to cause disease in humans.
Therefore, strains that do not cause disease would likely not be
collected. Comparisons between distinct lineages isolated from
the same geographic region should provide insight into how or-
ganisms exposed to similar geographical pressures have developed
distinct virulence strategies.
We corroborated the presence of -(1,3)-glucan in the cell wall
of WU24 and its requirement for macrophage killing in vitro, ex-
perimentally confirming that WU24 is indeed a chemotype II
strain. Furthermore, we demonstrated that WU24 is able to cause
disease in an immunocompetent host. Previous reports led to the
hypothesis that NAm 1 isolates only infect immunocompromised
patients; however, this was based on studies of one heavily pas-
saged isolate and three additional isolates that all came from HIV-
positive patients (27, 28). Histoplasmosis is more prevalent clini-
cally in patients with a depleted immune system, producing a
progressive and disseminated infection that frequently results in
death. H. capsulatum also infects and causes primary pulmonary
disease in healthy individuals, where it manifests as flu-like symp-
toms, is usually self-limiting and resolves, and is often not treated
clinically. In healthy individuals, the inoculum size has been pro-
posed to play a determining role in disease severity (44), and there
is limited anecdotal evidence that individuals with severe disease
have been exposed to a large dose of contaminated soil. In our
animal models, a sublethal dose resembles subclinical histoplas-
mosis, producing a symptomatic but nonlethal disease. Our data
revealed that inoculum size is an important factor in the degree of
virulence, pathogenesis, and fitness of different H. capsulatum
strains. This study illustrates the importance of considering mul-
tiple parameters in addition to fungal burden to quantify viru-
lence, including the ability to cause pulmonary inflammation,
time to fungal clearance from organs, and weight loss. Evaluation
of these parameters is especially important when comparing mul-
tiple strains.
Comparisons of these three individual strains at different doses
in a natural host were informative. At a high dose, G217B repli-
cated to a higher number in the lungs, persisted for a longer du-
ration, showed a delayed resolution of inflammation in the lungs,
and led to drastic weight loss in mice, compared to G186A and
WU24. These features of disease were not anticipated from in vitro
experiments with cultured macrophages, which are actually killed
more slowly by G217B. However, the most surprising results came
from experimental infections of mice exposed to a lower dose of
Histoplasma: G186A proved to be the more virulent strain, per-
sisting for a longer period than when administered at a high dose
and appearing to cause more inflammation in the lungs than
G217B or WU24. Perhaps at a higher dose, the absence of -(1,3)-
glucan enables easier recognition of G217B by the host immune
system, resulting in a heightened immune response that results in
a delayed resolution of inflammation, which is echoed in the cy-
tokine profiles. The increased TNF- in the lungs of G217B-
FIG 10 Levels of cytokines measured by ELISA in lungs of animals infected
with 2.5  103 yeast cells. (A) IFN- secretion at 0 (4 h), 4, 8, 12, 16, 20, and
32 days postinoculation. (B) TNF- secretion at 0 (4 h), 4, 8, 12, 16, 20, and
32 days postinoculation. A two-way repeated-measures analysis of variance
was performed. *, P  0.05; ns, not significant.
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infected mice may explain the increased weight loss in these mice,
given that TNF- is linked to cachexia-associated weight loss (45).
This was not seen at the lower dose, where the fungal burden may
have been below the threshold to trigger this higher level of in-
flammation by G217B. In fact, all three strains grew to similar
levels in the lung when inoculated at the lower dose, and the cor-
responding activation of IFN- and TNF- was very similar (and
low) for all strains. Interestingly, the kinetics of fungal prolifera-
tion, fungal clearance, and inflammation caused by chemotype II
strains are substantially shifted at the lower dose, suggesting that
the presence of -(1,3)-glucan may limit immune recognition and
cause a longer-lasting disease. For these strains, -(1,3)-glucan is
an essential virulence factor at high or low sublethal doses, as seen
in our previous studies with mutants defective in genes that are
required for -(1,3)-glucan production (ags1 and amy1).
Histoplasma is subjected to different evolutionary pressures
depending on its morphological state, and the selection and main-
tenance of yeast-specific virulence factors like -(1,3)-glucan is
only part of the picture. In the mycelial form, the soil environment
influences the evolution of specific traits, including the develop-
ment of conidia, which are considered the infectious particles
(along with fragments of mycelia) in this geographically wide-
spread zoonosis. Which is the “right” dose for assessing relative
strain virulence in an experimental infection? This is a difficult
question to answer with laboratory models of histoplasmosis;
even though the mouse is a natural host, intranasal inoculation of
yeast cells is typically substituted for aerosol exposure to conidia,
which are difficult to generate from most strains. An additional
complication is that natural infection is variable and a whole range
of doses can be encountered, which may be why multiple clades
have evolved within a particular geographic region. For example,
the abundance of H. capsulatum in midwestern U.S. soils (46)
might lead to more frequent high-dose infections. These condi-
tions may have enriched for the NAm 2 clade, which is a more
successful pathogen at a high dose. The low-dose infections could
have a more profound impact on fungal persistence, because the
immune response is much lower than that after high-dose expo-
sure. This would allow the fungus to establish a long-term infec-
tion, which would be an advantage for spreading to a new location
via animal host migration.
The development and progression of histoplasmosis have long
been known to represent a multifactorial relationship between the
immune status of the host and the pathogenicity of the fungus.
What is generally unappreciated is the need to consider both the
influence of strain background and of the infectious dose when
studying disease progression and making conclusions regarding
relative virulence. Our results indicate that the Histoplasma strain
and dose not only influence the assessment of virulence and the
kinetics of infection during the acute phase of the disease but also
can alter the resolution phase and the time required for fungal
clearance and ultimately host recovery.
MATERIALS AND METHODS
Fungal strains and culture conditions. The following Histoplasma capsu-
latum strains were used in this study: NAm 2 isolate G217B (ATCC
26032), Panamanian isolate G186A (ATCC 26029), and NAm 1 isolate
WU24 (a clinical strain isolated from an HIV-positive patient). We also
used an ags1() mutant of G186A, which has been previously described
(21). We generated a smooth mutant of WU24, WU24S, that was ob-
tained by enrichment of nonclumping yeast strains as described below. All
strains were grown in histoplasma macrophage medium (HMM) at 37°C
with 95% air–5% CO2 as previously described (47). Solid medium con-
tained 0.6% agarose (SeaKem ME grade) and 25 mM FeSO4. Dispersed
Histoplasma yeasts were obtained by growth of liquid cultures on an or-
bital shaker to late exponential phase, and cells were washed once with
warm (37°C) HMM, followed by a low-speed centrifugation (1 min at 600
 g) to remove large yeast clumps and counting with a hemacytometer.
To enrich for nonclumping yeast strains, log-phase yeast cells in broth
culture were centrifuged for 1 min at 600  g to remove large yeast
clumps. The remaining suspension of cells was removed and subcultured
in fresh medium. This process was repeated six times, after which the
suspension of cells was plated on HMM plates. The resulting colonies were
observed under a dissecting microscope. Colonies with a smooth appear-
ance were selected for further analysis.
Macrophage culture and virulence assay. P388D1 macrophage-like
cells were cultured in F-12 medium (Life Technologies) with 10% fetal
bovine serum (HyClone) or in HMM-M when coincubated with Histo-
plasma yeast cells, as described previously (48). Bone marrow-derived
macrophages were collected as previously described (49). Histoplasma
virulence in P388D1 cells was determined as previously described (21, 50).
Monolayers of P388D1 cells and BMDMs were infected in triplicate with
Histoplasma yeasts at a multiplicity of infection of 1:3 (yeasts:macro-
phages) in 24-well plates and incubated at 37°C in 95% air–5% CO2.
Fifty percent of the culture medium was replaced with fresh medium every
other day after day 3. After 3, 6, and 9 days of infection, culture medium
was removed, and remaining macrophages were lysed with a solution
containing 10 mM Tris, 1 mM EDTA, 0.05% SDS. The PicoGreen double-
stranded DNA quantification reagent (Molecular Probes) was used to
measure the amount of macrophage DNA in each well. Data represent
results collected from three independent assays.
Microscopy. Immunofluorescence and differential interference con-
trast (DIC) images were obtained using 4, 40, and 60 objectives on
an Olympus BX-60 microscope and collected using a SPOT-RT slider
charge-coupled-device camera and image acquisition software (Diagnos-
tic Instruments). Immunolocalization of cell wall -(1,3)-glucan was per-
formed by fixing exponentially growing broth cultures of yeasts in 4%
formaldehyde in phosphate-buffered saline (PBS) for 60 min at room
temperature and staining yeasts with a mouse monoclonal IgM antibody
that recognizes -(1,3)-glucan (number 401925; CalBiochem).
Murine colonization assay. All animal studies were approved by the
University of North Carolina in Chapel Hill Office of Animal Care and
Use, protocol 11-195. Male C57BL/6 mice (4 to 6 weeks old; Jackson
Laboratories) were sedated with ketamine/xylazine and infected intrana-
sally with sublethal doses of H. capsulatum yeast (2.5  105 or 2.5  103
dispersed cells in 20 l of HMM) as described previously (50). Six mice
per time point (4 for fungal burden and 2 for histopathology) were inoc-
ulated with each strain at each dose. Animals were sacrificed after 4 h and
4, 8, 12, 16, 20, and 32 dpi, and the lungs and spleens were removed and
homogenized in 5 ml of cold HMM. Serial dilutions of the homogenates
were plated on HMM plates to determine CFU recovered from each or-
gan. The body weight of the animals was monitored every 2 days during
the course of the infection.
Cytokine analysis. Aliquots from the lung homogenates used to de-
termine fungal burden in the lungs of infected mice were centrifuged at
16,000  g for 2 min and diluted 1/5 (for the high-dose samples) or 1/3
(for the low-dose samples). Levels of TNF-, IFN-, IL-1, and IL-12,
present in mouse lungs infected with the high dose and levels of TNF-
and IFN- present in mouse lungs infected with the low-dose were mea-
sured. All cytokine analyses were performed using the BD OptEIA
enzyme-linked immunosorbent assay (ELISA) set (BD Biosciences).
Based on our standard curves, the limit of detection for TNF- was 8 pg/
ml.
Histopathology. Uninfected mice and mice infected for 8, 12, 16, 20,
and 32 days were euthanized with sodium pentobarbital (150 mg/kg of
body weight), and their lungs were inflated with 10% formalin via cannu-
lation of the trachea. Lungs were removed and fixed in 10% formalin for at
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least 96 h and incubated in PBS for 2 h before being embedded in paraffin.
Five-micrometer sections of tissue were stained with hematoxylin and
eosin (H&E) before being examined.
Statistical analysis. Data were analyzed using Prism (GraphPad, CA).
P values of 0.05 were considered significant.
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